Johnson & Johnson announced withV-WaveReached a final acquisition agreement to acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for up to approximately $1.1 billion in additional regulatory and commercial milestone payments. Johnson & Johnson expects to complete the acquisition by the end of this year. Upon completion of the acquisition, Johnson & Johnson...Cardiac Recovery and Intravascular Lithotripsy DivisionPresident Michael Bodner will becomeV-WavePerson in charge.
"We are delighted to welcome V-Wave to Johnson & Johnson and take another significant step toward transforming the standard of care for cardiovascular diseases. We recognize the importance of identifying more diverse and effective treatments for heart failure, and our recent track record demonstrates our focus on accelerating impact for the most urgent and unmet needs. We have a deep understanding of V-Wave, and our relationship dates back to 2016, when weV-Wave for investment, we have a deep understanding of technology and science as well as V-Wave's commitment to patients. We look forward to collaborating with the V-Wave team during this critical phase of their development to help bring the V-Wave Ventura Shunt atrial shunt technology to patients."---Tim Schmid Johnson & JohnsonExecutive Vice President"At V-Wave, we are committed to the vision of helping patients around the world, and we know that Johnson & Johnson shares this mission. We believe that Johnson & Johnson has the ability to ensure that V-Wave's breakthrough ideas and technologies reach patients in need as quickly and effectively as possible. I am incredibly proud of the V-Wave team and their dedication to achieving this milestone. We look forward to continuing to build a world that prevents, treats, and cures cardiovascular diseases."
---Neal Eigler CEO of V-WaveAtrial shunt technology has always been highly controversial, with many people believing that this technology does not have significant clinical effects. However, Edwards and Johnson & Johnson invested in this technology years ago as two leaders in the field. Now, Johnson & Johnson has spent a substantial amount to acquire it and plans to make it an essential part of its future cardiovascular product portfolio. Johnson & Johnson believesVentura Interatrial ShuntIt is likely to become a first-line therapy for heart failure, filling the current treatment gap.Currently, there are numerous innovative medical device companies both in China and abroad developing various types ofAtrial shunt technology, supported by EdwardsCorvia Medical and Johnson & Johnson support V-Wave's progress the most. Both companies have large-scale clinical data. Although the efficacy study failed to reach the endpoint, both companies saw hope for atrial shunt devices in previous clinical study subgroups.InACC.24 in ChinaV-WavePublicationVentura Interatrial ShuntPreliminary Results of the RELIEVE-HF Pivotal Trial.The study showed that the primary efficacy endpoint was neutral, showing neitherVentura Interatrial ShuntThe relevant benefits also showed no harm. However, for subgroups (In patients with LVEF≤40%, the experimental group showed a 45% reduction in cardiovascular events compared to the placebo group (49.0% vs. 88.6%, RR 0.55), whereas in the patient population with LVEF>40%, the experimental group exhibited a higher rate of cardiovascular events (60.2% vs. 35.9%, RR 1.68). This demonstratesVentura Interatrial ShuntPotential clinical value, with extremely high safety.DespiteCorvia Medical andV-WaveClinical Trials Did Not Reach Endpoint, But Johnson & Johnson Makes Major AcquisitionV-Wave Will Inject Strong Momentum into the Gradually Cooling Atrial Shunt Device Track. BecauseJohnson & Johnson's Acquisition of Atrial Shunt Device Indicates Significant Focus on Huge Heart Failure (HFrEF) Market, Promising Substantial Commercial Returns for J&J in the Future.Chinese atrial shunt companies will usher in a new wave of capital enthusiasm; capital that hasn't boarded the train needs to hurry.
Ventura Interatrial Shunt Ventura Interatrial ShuntIt is a new type of hourglass-shaped implant, whichThere is a small opening in the middle, allowing blood to flow from the left atrium to the right atrium.
V-Wave Ventura ShuntThe novel hourglass design is intended to create a similar effect from the high-pressure atrium to the low-pressure atrium.WenThe Effect of the Churi Tube.This effect enhances the efficiency of blood transfer, allowing the shunt to be performed.GetSmaller.A Venturi tube is a pipe that first contracts and then gradually expands., which can generate the Venturi effect.That is, when the restricted flow passes through a narrowed cross-sectional area, the fluid velocity increases, and the velocity is inversely proportional to the cross-sectional area. Generally speaking, this effect refers to the phenomenon where high-speed flowing fluid creates a low-pressure area nearby, resulting in suction. This effect can be utilized to create a Venturi tube.
V-Wave Ventura ShuntDesign Features- Hourglass Stent (Nitinol): Designed to securely anchor the shunt device to the fossa ovalis, preventing migration or embolization of the shunt.
- Membrane (ePTFE): Aimed at restricting tissue growth and maintaining shunt patency.
Ventura Interatrial Shunt Demonstration
V-WaveFounded in Israel in 2009, focusing on developing percutaneous implantable technologies for patients with chronic heart failure.V-WaveDesign technology, with itsVentura Interatrial ShuntFocusing on helping heart failure patients alleviate symptoms, reduce hospitalization, and improve quality of life.
